Bio-Rad receives pre-market approval for HIV test from FDA

Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test. Because the testing kit was deemed a Class III medical device, it was required to undergo premarket approval – the FDA’s most...

Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study

Biotech company Ligand Pharmaceuticals Inc. (NASDAQ:LGND) reported Tuesday that its partner GlaxoSmithKline (NYSE:GSK, LON:GSK) received encouraging results from ENABLE-1 in a phase three study investigating Promacta in patients with hepatitis C thrombocytopenia. “We are pleased with...

E-Therapeutics expects to generate a “wealth of data” from clinical trials

E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates. This pipeline was identified using a platform called network pharmacology and spans cancer, infections and psychiatry. Having raised £16.6 million, the company is in a position to...

Inovio yields long-term immune responses from cervical cancer vaccine

Inovio Pharmaceuticals (AMEX:INO) reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV. In a follow-on study, the company’s SynCon DNA vaccine showed T-cell immune responses of up to over...

Novartis’ NVA237 improves lung function in pulmonary disease patients

Swiss drug maker Novartis (NYSE: NVS) said results from its phase three study of experimental drug NVA237 remarkably improved lung function in patients with a life-threatening respiratory disease, in a similar way to rival drug Tiotropium. A late stage study, named GLOW2, showed once daily use of NVA237, ...

Inherent value to be “developed and extracted” at Amphion

Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, when it released its annual results for 2010 this morning. Net asset value per share fell to 14 pence during the 12 months to 31 December, from 26 pence per...